BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Despite phase III failure of Zepzelca, Jazz and Pharmamar vow to forge ahead
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Despite phase III failure of Zepzelca, Jazz and Pharmamar vow to forge ahead
Dec. 3, 2020
By
Lee Landenberger
No Comments
The phase III study of Zepzelca (lurbinectedin) as combination therapy from Jazz Pharmaceuticals plc and Pharmamar SA was a stumble, but the companies said they found plenty of encouraging data prompting them to continue development.
BioWorld
Clinical
Cancer